SNSE (STOCKS)
Sensei Biotherapeutics, Inc. Common Stock
$13.850000
+0.850000 (+6.54%)
Prev close: $13.000000
Company Information
- Exchange
- XNAS
- Sector
- Health Technology
- Industry
- Biotechnology
- CEO
- Christopher W. Gerry
- Asset Type
- stocks
- Website
- Visit
Fundamentals
- Market Cap
- $19.04M
- Employees
- 15
- P/E (TTM)
- -0.72
- P/B (TTM)
- 0.88
- Dividend Yield
- —
Technical Indicators
- SMA 10
- —
- SMA 20
- —
- SMA 50
- —
- EMA 9
- —
- EMA 21
- —
- RSI
- —
- MACD State
- —
Analyst Recommendations
4
Strong Buy
4
Buy
2
Hold
0
Sell
Recent News
No recent news found for this ticker.
Earnings Surprises
| Period | Actual | Estimate | Surprise | Surprise % |
|---|---|---|---|---|
|
Mar 2026 (Q1)
|
$-28.79 | $-0.63 | -28.1576 | -4,452.50% |
|
Dec 2025 (Q4)
|
$-3.74 | $-4.91 | +1.1662 | +23.77% |
|
Sep 2025 (Q3)
|
$-3.62 | $-4.19 | +0.5722 | +13.65% |
|
Jun 2025 (Q2)
|
$-3.91 | $-5.71 | +1.8020 | +31.55% |
Financial Statements
| Revenues | $0.00 |
| Operating Expenses | $185.64M |
| Operating Income/Loss | -$185.64M |
| Income/Loss From Continuing Operations After Tax | -$181.84M |
| Income/Loss From Continuing Operations Before Tax | -$184.46M |
| Income Tax Expense/Benefit | -$2.62M |
| Net Income/Loss | -$184.46M |
| Net Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Net Income/Loss Attributable To Parent | -$184.46M |
| Net Income/Loss Available To Common Stockholders, Basic | -$184.46M |
| Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0.00 |
| Preferred Stock Dividends And Other Adjustments | $0.00 |
| Basic Earnings Per Share | -$142.72 |
| Diluted Earnings Per Share | -$142.72 |
| Basic Average Shares | 3,817,412 |
| Diluted Average Shares | 3,817,412 |
| Assets | $205.38M |
| Current Assets | $204.23M |
| Prepaid Expenses | $974.00K |
| Other Current Assets | $203.26M |
| Noncurrent Assets | $1.15M |
| Fixed Assets | $69.00K |
| Other Non-current Assets | $1.08M |
| Liabilities | $14.19M |
| Current Liabilities | $14.19M |
| Accounts Payable | $3.42M |
| Wages | $4.17M |
| Other Current Liabilities | $6.60M |
| Noncurrent Liabilities | $1.00K |
| Redeemable Noncontrolling Interest | $328.48M |
| Redeemable Noncontrolling Interest, Preferred | $328.48M |
| Equity | -$137.29M |
| Equity Attributable To Noncontrolling Interest | $0.00 |
| Equity Attributable To Parent | -$137.29M |
| Temporary Equity | $328.48M |
| Liabilities And Equity | $205.38M |
| Net Cash Flow From Operating Activities | -$24.09M |
| Net Cash Flow From Operating Activities, Continuing | -$24.09M |
| Net Cash Flow From Investing Activities | -$18.86M |
| Net Cash Flow From Investing Activities, Continuing | -$18.86M |
| Net Cash Flow From Financing Activities | $185.40M |
| Net Cash Flow From Financing Activities, Continuing | $185.40M |
| Net Cash Flow | $142.45M |
| Net Cash Flow, Continuing | $142.45M |
| Comprehensive Income/Loss | -$184.47M |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Comprehensive Income/Loss Attributable To Parent | -$184.48M |
| Other Comprehensive Income/Loss | -$18.00K |